Noeul-Iwon Medical Foundation Collaborate on AI-Based Diagnostic Platform Development

Noeul, an artificial intelligence (AI)-based blood and cancer diagnostic platform company, announced on the 4th that it has signed a joint business agreement (MOU) with Ewon Medical Foundation, a professional clinical testing institution, for the development of an AI-based diagnostic platform.

Lee Deok-gu, Chairman of Lee Won Medical Foundation (left), and Lim Chan-yang, CEO of Noeul, are posing for a commemorative photo after signing a joint business agreement for the development of an AI-based diagnostic platform.
[Photo by Noeul]

This business agreement was made to focus on mutual exchange for the automation of in vitro diagnostic testing and the advancement of interpretation performance by combining Noeul's AI diagnostic platform development capabilities with Ewon Medical Foundation's diagnostic service capabilities. Ewon Medical Foundation aims to improve the efficiency of diagnostic testing in the fields of blood tests and tissue tests, while Noeul expects to strengthen its AI capabilities and expand its market through the expansion of new AI product lines.

Im Chanyang, CEO of Noeul, stated, “This business cooperation is an important milestone for the digitalization of in vitro diagnostic testing,” adding, “Based on Noeul’s AI technology, we will establish a foundation to expand into interpretation areas for various cancer types such as stomach cancer and colorectal cancer.” Lee Deokgu, Chairman of Ewon Medical Foundation, also said, “The medical field is currently experiencing a time of various changes and innovations, including AI, automation, and digitalization,” and added, “We expect that the capabilities accumulated by Ewon Medical Foundation through 40 years of diagnostic testing services will meet Noeul’s future-oriented technology to provide global-level in vitro diagnostic testing services.”

This content was produced with the assistance of AI translation services.